21世纪经济报道记者 凌晨 西安报道 质押展期、入不敷出，昔日区域医疗服务龙头国际医学（000516.SZ ）能否经受住风雨？ 最新披露财报显示，2025年上半年，国际医学延续亏损态势，预计归属于上市公司股东的净利润亏损区 间为1.6亿元至1.7亿元，与上年同期的1.74亿元亏损相比，减亏幅度有限，突显经营造血能力的持续不 足。 引发关注的是，该公司控股股东质押率加速攀升。数据显示，世纪新元及其一致行动人的股权质押比例 高达27.49%，占其所持股份的81.45%，占总股本的22.39%。 尽管公司强调质押融资仅为大股东自身资金需求，不影响日常运营，但这一高杠杆水平无疑将潜在债务 风险传导至上市公司层面，特别是在现金流面临持续缩窄的环境中。 预亏数据的供血乏力叠加高质押风险，令这家医疗企业直面资金流紧张与债务滚雪球效应的双重挑战。 能否穿越风暴？答案取决于公司如何平衡成本管控、政策应对与股东质押风险缓释。 亏损黑洞 国际医学正深陷业绩泥沼，2018年以来扣非净利润连续七年为负的残酷现实，正在考验着这家大型医疗 集团的生存韧性。 2025年上半年业绩预告再度预警，虽较上年同期1.74亿元亏损稍有收窄，但经营压力 ...

3．业绩预告情况表 | 归属于上市公司 股东的净利润 | 亏损：17,000.00万元 | –16,000.00万元 | 亏损：17,360.58万元 | | --- | --- | --- | --- | | 扣除非经常性损 益后的净利润 | 亏损：19,200.00万元 | –18,200.00万元 | 亏损：13,890.46万元 | | 基本每股收益 | 亏损：0.0760元/股 | –0.0715元/股 | 亏损：0.0768元/股 | | 营业收入 | 201,000.00万元 | –205,000.00万元 | 242,046.17万元 | 证券代码：000516 证券简称：国际医学 公告编号：2025-033 西安国际医学投资股份有限公司 2025 年半年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 1. 业绩预告期间：2025年1月1日-2025年6月30日 2．预计的业绩：√预计净利润为负值 影响，营业收入同比下降。公司在采取调整业务结构，实施降本增效等措 施逐步改善经营成效，但营业收入总规模尚未能覆盖运营成本和期间费用。 本 ...

Market Overview - The Shanghai Composite Index closed at 3519.65 points, above the annual line, with a change of 0.27% [1] - The total trading volume of A-shares reached 14809.22 billion yuan [1] Stocks Breaking Annual Line - A total of 46 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Huaming Equipment (002270) with a deviation rate of 2.75% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.63% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, latest price 76.99 yuan, deviation rate 7.62% - Huaming Equipment: 3.25% increase, latest price 16.85 yuan, deviation rate 2.75% - Tongyi Co., Ltd.: 2.63% increase, latest price 16.02 yuan, deviation rate 2.63% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Daqin Railway and *ST Haiyuan with minimal deviation rates [1]

Market Overview - The Shanghai Composite Index closed at 3525.40 points, above the annual line, with a change of 0.43% [1] - The total trading volume of A-shares reached 987.43 billion yuan [1] Stocks Breaking Annual Line - A total of 41 A-shares have surpassed the annual line today, with notable stocks including: - Siyuan Electric (002028) with a deviation rate of 7.62% - Tongyi Co., Ltd. (300538) with a deviation rate of 2.51% - Ruisheng Technology (688090) with a deviation rate of 2.05% [1] Stocks with Significant Deviation Rates - The stocks with the highest deviation rates from the annual line include: - Siyuan Electric: 10.00% increase, trading at 76.99 yuan - Tongyi Co., Ltd.: 2.50% increase, trading at 16.00 yuan - Ruisheng Technology: 3.24% increase, trading at 35.10 yuan [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Qianjiang Motorcycle, Jiuquan Technology, and Huadian International, which have just reached the annual line [1]

证券代码：000516 证券简称：国际医学 公告编号：2025-032 西安国际医学投资股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控 股股东陕西世纪新元商业管理有限公司（以下简称"世纪新元"）的通 知，世纪新元使用其持有的本公司部分股份与长安国际信托股份有限公 司进行的融资类质押已于近期办理了部分股份解除质押手续。具体事项 如下： | 股东 | 是否为控股股东 | 本次解除质押 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 或第一大股东及 | 股份数量（股） | | | | | | | | 其一致行动人 | | 比例 | 比例 | | | | | 世纪 | 是 | 32,440,000 | 5.27% | 1.45% | 2023 年 12 | 2025 年 7 | | | 新元 | | | | | 月 ...

Core Viewpoint - The recent study published in the British Medical Journal demonstrates that surgical intervention can effectively treat aphasia in chronic stroke patients, highlighting the importance of surgical innovation alongside traditional medical advancements [1][2]. Group 1: Research Findings - The study involved 50 stroke patients with language impairments, randomly divided into two groups: one receiving the NC7 surgery and intensive speech therapy, while the other received only speech therapy [2]. - Results showed that the NC7 group had an average improvement of 11.16 points on the Boston Naming Test (BNT) after one month, significantly outperforming the control group's 2.72 points, with improvements remaining stable after six months [2]. - The NC7 surgery, which takes approximately 40 minutes and is cost-effective, is suggested as a viable option for doctors worldwide treating post-stroke aphasia patients [2]. Group 2: Surgical Innovation - The NC7 surgery was inspired by previous observations from a different surgical procedure (CC7 surgery), where some patients exhibited unexpected improvements in language function shortly after surgery [3]. - The hypothesis suggests that the rapid improvement in language abilities may be due to neural regulatory effects rather than traditional nerve regeneration [3][4]. - The development of the NC7 surgery represents a new treatment method for aphasia, moving from clinical discovery to systematic validation over seven years [4]. Group 3: Broader Implications - The advancement of technologies such as AI and brain-machine interfaces raises questions about the role of physicians in the evolving medical landscape, emphasizing the need for clinical observation and innovation [4]. - The study calls for a reevaluation of rehabilitation models and policies in light of these findings, advocating for a balance between embracing new technologies and maintaining a focus on clinical phenomena [2][4].

Group 1 - The stock price of International Medical (000516) closed at 5.16 yuan on June 27, 2025, up 2.18% from 5.05 yuan the previous week [1] - The highest intraday price reached 5.26 yuan on June 27, while the lowest was 5.00 yuan on June 23 [1] - The current total market capitalization of International Medical is 11.553 billion yuan, ranking 13th out of 50 in the medical services sector and 1396th out of 5151 in the A-share market [1] Group 2 - The controlling shareholder, Century Xinyuan, pledged 48.9 million shares, accounting for 2.18% of the company's total share capital [1] - The pledged shares represent 81.45% of Century Xinyuan's holdings, which total 616,061,198 shares, or 27.49% of the company [1] - The total number of pledged shares due within the next six months is 151.43 million, representing 24.58% of Century Xinyuan's total holdings and 6.76% of the company's total share capital, with a corresponding financing amount of 242 million yuan [1] - Within the next year, the total number of pledged shares is 319.83 million, accounting for 51.92% of Century Xinyuan's holdings and 14.27% of the company's total share capital, with a financing amount of 586 million yuan [1] - Century Xinyuan has a good credit status and strong repayment capability, with no current risk of forced liquidation of the pledged shares, and it does not materially affect the company's operations or governance [1]

证券代码：000516 证券简称：国际医学 公告编号：2025-031 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质 | 本次质 | 占其 | 占公 | 情况 | | 情况 | | | | | | 押前质 | 押后质 | | | | | | | | 股东 | 持股数量 | 持股 | | | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | | | | 押股份 | 押股份 | | | | | | | | 名称 | （股） | 比例 | | | 股份 | 股本 | 份限售和 | 质押 | 份限售和 | 质押 | | | | | 数量 | 数量 | | | | | | | | | | | | | 比例 | 比例 | 冻结数量 | 股份 | 冻结数量 | 股份 | | | | | （股） | （股） | | | | | | | | | | | | | ...

证券代码：000516 证券简称：国际医学 公告编号：2025-030 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | | | | 本次解 | 本次解 | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 情况 | | 情况 | | | 股 | | | 除质押 | 除质押 | 占其 | 占公 | | | | | | 东 | 持股数量 | 持股 | 前累计 | 后累计 | 所持 | 司总 | 已质押 | 占已 | 未质押股 | 占未 | | | | | | | | | 股份限 | | | | | 名 | （股） | 比例 | 质押股 | 质押股 | 股份 | 股本 | | 质押 | 份限售和 | 质押 | | 称 | | | 份数量 | 份数量 | 比例 | 比例 | 售和冻 | 股份 | 冻结数量 | 股份 | | | | | | | | | 结数量 | | | | | | | | （股） | （股） | | | | 比例 | ...

Group 1 - The company received a notification from its controlling shareholder, Shaanxi Century Xinyuan Commercial Management Co., Ltd., regarding the pledge of its shares on June 13, 2025 [1] - The pledged shares amount to 60,000,000, representing 9.74% of the shares held by the controlling shareholder and 2.68% of the total share capital of the company [1] - The pledge is for financing purposes and does not involve any lock-up shares [1] Group 2 - As of the announcement date, the total pledged shares by Century Xinyuan and its concerted actors amount to 718,645,251, which is 32.07% of the shares held by them and 68.16% of the total share capital of the company [2] - The financing amount corresponding to the pledged shares is 4.77 billion yuan, with 307,930,000 shares maturing within the next year, representing 49.98% of the shares held by the controlling shareholder [2] - The company states that there is no risk of forced liquidation for the pledged shares, and the controlling shareholder has a good credit status and strong repayment ability [2]